- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04810208
Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours
Studie Overzicht
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Copenhagen, Denemarken
- Herlev Hospital
-
-
-
-
-
Kaunas, Litouwen
- Lithuanian University of Health Sciences
-
Vilnius, Litouwen
- National Cancer Institute
-
-
-
-
-
Stockholm, Zweden
- Karolinska University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Signed written informed consent granted before undertaking any study-specific procedures;
- Male or female patient ≥18 years of age on the day of consenting to the study;
- Histologically or cytologically confirmed diagnosis of solid cancer;
At least 1 advanced solid, palpable, cutaneous or subcutaneous tumour lesion with following characteristics:
- a cutaneous lesion with of thickness ≥4 mm and diameter ≥25 mm at the longest axis, or
- a subcutaneous lesion of diameter ≥20 mm at the longest and the shortest axis;
- Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0-2;
Patient from one the following categories:
- Patient for whom no standard therapy exists, or standard therapy is contraindicated, or
- Patient who is scheduled for other anti-cancer treatment (e.g. radiotherapy, immunological treatment, surgery) which will start after completion of at least one treatment cycle of NZ-DTX, i.e after the end-of-study (EOS) visit.
Exclusion Criteria:
- Known hypersensitivity to any of the excipients in the NZ-DTX Depot formulation (docetaxel, calcium sulphate, sodium carboxymethylcellulose);
- Life expectancy <3 months;
- Bleeding deficiencies or ongoing anticoagulant therapy that would put the patient at increased risk of clinically significant bleeding, in the judgement of the Investigator. If the patient has an international normalised ratio (INR) below 1.2 the Investigator may judge if interruption of anticoagulant therapy is warranted;
Any of the following abnormal laboratory values at screening;
Bone marrow function:
- Absolute neutrophil count (ANC) <1.5 x 109/l;
- Platelet count <100 x 109/l;
- Haemoglobin <9.0 mg/dl.
Coagulation:
- International Normalized Ratio (INR) >1.2.
Hepatic, renal, and biochemistry parameters:
- Aspartate transaminase (AST) or alanine transaminase (ALT) >2.5 x upper limit of normal (ULN) (>5 x ULN if liver metastases present)*;
- Alkaline phosphatase (ALP) >2.5 x ULN;
- Total bilirubin >1.5 x ULN;
Estimated glomerular filtration rate (eGFR) <40 ml/min/1.73 m² using the Modified Cockcroft & Gault formula.
- For patients with liver impairment who have serum transaminase levels (ALT and/or AST) greater than 1.5 times x ULN - the doses will be restricted to max. 75mg/m2. In the event this is not possible the patient will not be included.
- Severe fluid retention, e.g. pulmonary oedema, pleural effusion, pericardial effusion or ascites;
- Clinically significant heart disease (i.e. heart failure or myocardial infarction within 6 months of screening, instable angina pectoris);
- History of thromboembolic or cerebrovascular events within 6 months of screening;
- Major surgery within 2 weeks of screening, or patient not recovered from major surgery;
- Known untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of screening;
- Not recovered from Grade 2 or higher adverse events (AEs) due to previous treatments, excepting alopecia;
- Concurrent participation in another investigational study;
- Last investigational drug administration in a prior investigational study within 14 days of study treatment initiation or <5 times the half-life of the investigational drug, whichever is longer;
- Last administration of other anti-neoplastic drug within 14 days of study treatment initiation;
- Radiotherapy of lesion to be injected within 4 weeks of first treatment with NZ-DTX Depot, or irradiated lesion to be injected without signs of disease progression since irradiation;
- For men and women of childbearing potential: Unwillingness to follow contraception requirements;
- Female patients with planned or current pregnancy and/or currently breastfeeding;
- Any other severe, acute or chronical medical or psychiatric condition or laboratory abnormality that, in the judgement of the Investigator, would make the patient inappropriate for study participation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: NZ-DTX Depot
|
Docetaxel in NanoZolid formulation, for intratumoural injection
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.
Tijdsspanne: 5 weeks
|
The MTD will be determined by incidence of DLTs
|
5 weeks
|
|
The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.
Tijdsspanne: 5 weeks
|
The RP2D will be determined by frequency and severity of adverse events
|
5 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency and severity of treatment-emergent adverse events [safety and tolerability] following an intratumoural injection of NZ-DTX Depot
Tijdsspanne: 5 weeks
|
Frequency and severity of treatment-emergent adverse events
|
5 weeks
|
|
Plasma concentration of docetaxel, following an intratumoural injection of NZ-DTX Depot
Tijdsspanne: 5 weeks
|
Plasma concentration of docetaxel
|
5 weeks
|
|
Anti-tumour effect following an intratumoural injection of NZ-DTX Depot
Tijdsspanne: 5 weeks
|
Tumour response by RECIST
|
5 weeks
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Presence of immune biomarkers in plasma, following an intratumoural injection of NZ-DTX Depot
Tijdsspanne: 9 weeks
|
Analysis of cytokines in plasma
|
9 weeks
|
|
Presence of immune biomarkers in tissue, following an intratumoural injection of NZ-DTX Depot
Tijdsspanne: 9 weeks
|
Immunohistochemistry analysis [PD-L1] in tissue
|
9 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Charlotta Gauffin, PhD, Lidds AB
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NZ-DTX-001
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .